 Neurodevelopmental disorders (NDDs) are severely debilitating neuropsychiatric illnesses.
related NDD, affecting females and causing stereotyped hand movements, microcephaly (see further), as well as cognitive and social deficits [137] .
Motor disorders present with impaired execution of motor skills, or repetitive motor behaviors, including developmental coordination and stereotypic movement disorders [4] (Fig. 1 ). Tic disorders are characterized by habitual motor movements or vocalizations which are sudden, rapid, recurrent and nonrhythmic. This group of NDDs includes Tourette's disorder, persistent (chronic) motor or vocal tic disorder, provisional tic disorder, as well as other tics [4] . Tuberous sclerosis complex (TSC) is characterized by benign brain tumors (tubers), often presenting with ID and varying developmental delays [46] . Structural brain disorders, such as microcephaly and lissencephaly, form a distinct group of NDDs with specific genetic and environmental causes [92] . Microcephaly, diagnosed as head circumference two standard deviations below the mean for a child's age and sex, often co-occurs with ID and speech delays [197] . Lissencephaly is a rare genetic disorder that results in a brain lacking gyri and folding, and manifests behaviorally in seizures, hypotonia, and ID resulting from the overall psychomotor impairment [69] .
Finally, specific environmental factors can also trigger NDD pathogenesis. For example, prenatal exposure to alcohol is a key risk factor for a range of morphological phenotypes and mental retardation collectively referred to as Fetal Alcohol Syndrome (FAS, Fig. 1 ) [101] . FAS represents the main nonhereditary cause of ID, affecting approximately 2-5% of live births [129] . Relatively low doses of alcohol can also affect cognition, behavior and brain morphology (referred to as Fetal Alcohol Spectrum Disorders, FASD), implicating even moderate drinking during pregnancy as a risk for NDD pathogenesis [82, 163, 169, 182] (see further).
In general, NDDs are severely debilitating brain illnesses ( Fig. 1 ) with significant societal impact [61] . Given the lack of efficient targeted therapies, it is important to gain further translational insights into the pathobiology of these disorders [88] . To address this problem, the International Stress and Behavior Society (ISBS) has established the Strategic Task Force on NDDs, an international team of independent clinical and preclinical experts [88] . Complementing the Panel's recommendations on improving NDD pharmacotherapy [88] and preclinical behavioral models [2] , here we discuss the neurobiological and genetic mechanisms of several common NDDs, and outline further strategic directions of research of their key affected (social, cognitive and motor) domains. This review does not intend to provide a comprehensive coverage of all NDDs, and acknowledges the existing limitations of animal (preclinical) models of these disorders.
Genetics of neurodevelopmental disorders
NDDs are highly heritable disorders [20, 28, 114] . While recent genetic technology has enabled the identification of numerous genes for various NDDs [91] , their exact pathogenetic mechanisms remain unclear [206] . Our understanding of NDDs is complicated by their polygenic nature and de novo mutations in multiple genes (often resulting in similar clinical phenotypes) identified by whole-exome and whole-genome sequencing [94, 131, 146, 184] . Novel mutations are recurrently seen in such key cellular genes as CHD8, DYRK1A, GRIN2B and PTEN [145] , thereby affecting normal growth and development of the brain. Genetic analyses empower the search for candidate genes for NDDs, whose psychiatric symptoms co-occur with other, non-mental phenotypes (e.g., altered facial morphology and cardiac defects) [19, 29] . For example, FXS is caused by the expanded CGG repeat in the promoter of the FMR1 gene [71, 193] , resulting in distinguishing facial features [121] , ID, speech delay and repetitive behaviors [18, 206] . FMR1 codes for the fragile X mental retardation protein (FMRP), which acts as a negative regulator of mRNA translation in neurons [143] , and its genetic ablation in mice markedly decreases dendritic spine density in the brain -a phenotype also seen in human postmortem FXS samples [41, 95, 143] .
Caused by loss of one copy of the UBE3A (Ubiquitin Protein Ligase E3A) gene [110, 125, 128] , AS-related ID, stereotyped behavior and hyperactivity [9, 40] parallel decreased dendritic spine density and impaired long-term potentiation/depression seen in Ube3a knockout rodents [168, 200] . In general, such common deficits in dendritic spine density in NDDs highlights the importance of synaptic processes in neural development [205, 206] . For instance, mutations in SHANK3 (encoding a scaffolding synaptic protein [134, 166, 187] ) cause developmental delay, neonatal hypotonia, decreased socialization and increased stereotypy clinically [152] . Similar to SHANK3, the neuroligin and neurexin protein families involved in synaptic scaffolding, are also implicated in ASD [206] . Mutations in the NEUROLIGIN3 (NLGN3) and NEUROLIGIN4 (NLGN4) genes were among the first causative mutations identified in ASD patients [98] . In line with this, Nlgn knockout mice show specific deficits in excitatory (Nlgn1) or inhibitory (Nlgn2) synaptic transmission [39] , and social deficits (nlgn3 and nlgn4), a key behavioral symptom of ASD [98, 158] .
Mutations in MECP2 (encoding the methyl-CpG-binding protein 2, MeCP2) are responsible for the majority of cases of Rett syndrome [137] , which is highly comorbid with ASD. MeCP2 is abundant in post-mitotic neurons and binds to methylated cytosines in DNA [117, 174] , functioning as both a transcriptional repressor and activator [32, 188] . Implication of genes encoding chromatin-modifying enzymes in ASD [51] is not surprising, given the association of MECP2 with Rett syndrome [33, 78] .
Likewise, Mecp2 mice are a useful model of human Rett syndrome [33, 36, 77, 174] , showing aberrant synaptic plasticity and deficient long-term potentiation in genetic knockout [15, 132] . Interestingly, targeted deletion of Mecp2 in gamma aminobutyric acid (GABA)-ergic neurons recapitulates many core Rett phenotypes, including reduced GABA-ergic neurotransmission [35] .
Recently identified risk genes for ID include SYNGAP1 (encoding the synaptic Ras-GTP activating protein 1) and SNAP25 (encoding synaptosomal-associated protein 25) regulating synaptic signaling and neurotransmission, respectively [75, 81, 105] . SNAP25 is also a risk locus for ADHD, along with genes encoding proteins involved in dopaminergic and serotonergic neurotransmission, such as dopamine receptors D4 (DRD4) and D5 (DRD5), dopamine transporter DAT (SLC6A3), serotonin transporter SERT (SLC6A4), and serotonin 1B receptor (HTR1B) [74, 119] . In summary, these and many other examples, including Down, Williams, Prader-Willi and Angelman syndromes and even schizophrenia ( Table 1) , strongly support the critical role of genetic factors in both clinical NDDs and their genetic animal models, collectively providing important mechanistic insights into pathobiology of NDDs.
Environmental factors influencing risk for NDDs
In addition to genetic determinants, a wide range of environmental factors can impact neural development ( Fig. 2) . Beginning in utero, these postconception influences involve the nutritional and physiological (e.g., hormonal or infectious) status of the mother, as well as her lifestyle and use of medications (e.g., selective serotonin reuptake inhibitors, SSRIs or valproate) [45, 59, 122] . Some of these factors, such as postnatal nutrients, hormones, infections, the microbiome and parenting, potently modulate neural development [100, 113, 142] , and will be discussed here in detail.
Pre-natal environmental factors modulating neural development
The placenta transfers nutrients, hormones, drugs and inflammatory factors from the mother to the fetus. For example, placental function affects perfusion of the fetus, and therefore can influence neural development. Nutritional factors, consumed by the mother and relevant for fetal neurodevelopment, include fat-soluble vitamins (e.g., A, D, E), tryptophan and nutrients related to single carbon metabolism (e.g., choline, vitamins B2, B6, B12 and folate) [59, 60] . Tryptophan, a food-derived essential amino acid, serves as a precursor of serotonin and melatonin, but is also subject to degradation by indoleamine 2,3-dioxygenase, one of three enzymes catalyzing the first step of the kynurenine pathway of tryptophan degradation. While melatonin is one of the main sources of mitochondrial protection, it acts as antioxidant in the placenta and, as shown in mouse studies, facilitates the transport of folate from maternal circulation through the placentas into the fetus [70] . Folate deficiency has been associated with neural tube defects [47] and, as a B-vitamin, is important for CNS cell repair [96] , genome epigenetic modulation [179] and immune mechanisms [111] .
As already mentioned, exposure to alcohol during pregnancy is a key risk factor in NDDs, such as FAS [101] and FASD [82, 163, 169, 182] . Sonic hedgehog (SHH) signaling is of special interest in FAS owing to its role in proper craniofacial development. During early neural crest migration, ethanol reduced Shh mRNA expression in the chick embryo and caused cell death in cranial neural crest cells, an effect rescued by exogenous Shh administration [3] . FAS and FASD are closely related to the umbrella term "alcohol-related neruodevelopmental disorder" (ARND), representing a facet of NDD pathogenesis associated with history of maternal alcohol exposure ( Fig. 1 ). In addition to rodents, other newly emerging model organisms, such as zebrafish (Danio rerio), can be useful to study various aspects of FAS and ARND. For example, zebrafish models link early ethanol effects with aberrant craniofacial morphology [22] , as well as deficits in social behavior and increased perseveration on a learning task [149, 150] . These behavioral changes corresponded to changes in nicotinic, dopaminergic, serotonergic and µ-opioid receptor gene expression, suggesting that ethanol during development impacts neurotransmitters and receptor expression, causing long-term behavioral effects. The effects of prenatal exposure to ethanol is dependent on the timing of exposure and the dose to which the fetus is exposed, but may also depend on the fetal and maternal genotype. A screen of alcohol-exposed mutant zebrafish revealed several alcohol-sensitive alleles [183] , including the gene encoding platelet derived growth factor receptor α (pgdfra), a mitogen involved with neural crest cell migration and causing craniofacial abnormalities in 63% of heterozygotes after exposure to 1% alcohol. This finding is particularly interesting as it revealed alcohol-induced haploinsufficiency and was also identified as a potential locus of interest in a GWAS of humans with FAS. Similarly, the PCP gene vangl2, which is responsible for neural tube development, is associated with an increased risk of ethanol-induced teratogenesis in heterozygotes, revealing ethanol-induced haploinsufficiency that merits special interest from the NDD/ARND perspective [183] .
Other parental influences
Post-conception maternal stress has a major impact on fetal neural development, especially given mounting evidence that early life stress increases risk to various childhood/adulthood disorders. For instance, maternal stress during pregnancy is associated with an increased incidence of ADHD and ASD, as well as cognitive deficits and emotional/behavioral problems in children later in life [141] . Animal studies suggest that the neuroendocrine hypothalamic-pituitary-adrenal (HPA) axis is particularly vulnerable to early-life programming by stress and subsequent epigenetic modification of glucocorticoids-related genes [123] . Since glucocorticoids promote neuronal survival and differentiation, myelination, dendritic growth and synaptogenesis [107] , maternal stress can have a substantial impact on fetal neural development and increase the risks for NDDs [196] . Pregnancy itself is a risk factor for various brain disorders, such as depression. Because of the detrimental effects of maternal depression on mother and fetus, mothers may receive antidepressant pharmacotherapy during pregnancy, including SSRIs. However, SSRIs readily cross the placenta in both humans and mice [139] and can alter serotonin homeostasis, thereby affecting neural development. Prenatal SSRI exposure in mice increases anxiety in later life, similar to phenotypes of SERT mutant mice [11] . Clinical studies also report that prenatal SSRI exposure has neurodevelopmental consequences for offspring, ranging from newborn withdrawal symptoms [133] to delayed motor development, socio-emotional changes [83] , ASD [23, 45, 63] (but see [31] ) and ADHD [66] . Given similar neurodevelopmental consequences of prenatal SSRI exposure in rodents [106, 109] , changes in neurotransmitter levels during early brain development may have a major impact on NDD-related phenotypes. Another common example of NDD-relevant prenatal drug exposure is valproic acid. Prescribed for maternal epilepsy and some neuropsychological disorders, this agent significantly increases risk for ASD in humans [38] , and its early exposure causes similar ASD-like behavioral deficits in a wide range of animal models, including rodents [170] , tadpoles [99] and zebrafish [16] .
Fetal immune activation (e.g., as a result of maternal infections) may also modulate neural development. These immune interactions are complex, as maternal placenta itself contains natural killer cells and macrophages [64] the immune cells that can influence the development of the placenta. This, in turn, can affect the fetal microenvironment (e.g., by modulating the perfusion of the fetus) [126] . Furthermore, cytokines induced by maternal immune activation and maternal antibodies can cross the placenta [203] , which can exert a negative impact on brain development if the time of exposure overlaps with major processes in neurodevelopment, such as cell migration, axonal elongation and dendritic tree maturation [21] . While this may increase the risk of NDDs [53] [30, 85] , peripheral activation of the fetal immune system can also modulate the CNS indirectly, by activating the HPA axis [177] . Because the blood-brain barrier is not fully developed during the fetal period, larger molecules, such as antibodies, may have greater access to the brain [55] . The blood-brain barrier permeability increases as a result of microglia cell activation, infection, trauma or stress, therefore enhancing the risk of exposing the brain to insults and environmental stimuli that affect neural development [156] .
Another important factor in fetal neural development is maternal genotype. For example, maternal SERT promoter region 5-HTTLPR genotype affects the development of children, with their neuroimaging phenotypes and cognitive performance differing between the 5-HTTLPR SS and LL mothers [190] .
Although all children carried the L/S genotype, somatosensory cortex grey matter density and fine motor task performance were greater in children of the SS mothers [190] . In another human study, familial analyses of the tryptophan hydroxylase 1 gene TpH1 mutation carriers (that have deficiency in serotonin production in the periphery, but not in the brain) revealed that offspring of mothers carrying TpH1 mutations exhibited higher ADHD scores and related symptoms than did controls or offspring of fathers with the corresponding TpH1 mutations [79] . Similarly, mouse fetuses (fully capable of producing serotonin in the brain) conceived by a TpH1 knockout mother deficient in the peripheral serotonin, had an abnormally shaped cortex [42, 144] . Thus, prenatal influences and maternal genotype have profound effects on neural development in offspring, and are therefore highly relevant to NDD pathogenesis.
Post-natal environmental factors modulating neural development
Microbiome is a key post-natal environmental factor to consider for NDDs, since gestational age, mode of delivery, bacterial environment and use of antibiotics can all influence the composition of the gut microbiota of the newborn [100, 144] . For example, bacteria in the gut influence the immune system, as well as tryptophan availability and peripheral monoamine levels [144] . Germ-free animals exhibit increased plasma tryptophan concentrations which can be normalized by colonization immediately post-weaning [144] . Germ-free mice show robust changes in the brain, including increased hippocampal serotonin concentrations -an alteration resistant to the subsequent normalization of circulating tryptophan following the introduction of a gut microbiota immediately post-weaning [144] . Although peripheral tryptophan may be converted to serotonin in the brain, it can also be subject to the indoleamine 2,3-dioxygenase pathway, being converted to kynurenine and therefore becoming unavailable for serotonin synthesis [201] . Microbiota influence the kynurenine:tryptophan balance [144] , and this shift towards kynurenine activates the immune system [48] , thereby indirectly affecting postnatal neural development.
Parenting per se also has a major impact on postnatal neural development. A well-known example is the effect of maternal adversity in humans and rodents on development of offspring [7] . In humans, childhood maltreatment (often dependent on parent-offspring social interactions) is associated with an increased HPA response to stress [7] . In rodents, low maternal grooming of pups increases stress reactivity of the HPA-axis by altering serotonin-dependent epigenetic regulation of glucocorticoid receptors in the hippocampus and the glucocorticoid negative feedback [6, 7] . These effects are also accompanied by changes in dendritic morphology of hippocampal pyramidal neurons and pronounced behavioral effects, such as reduced exploration, appetitive behavior and escape from threat, and increased fear-related memories [7] [34] .
Other environmental factors, including environmental enrichment (EE) and exercise, have been investigated as potential interventions for NDDs in animal models. For example, in a rat ASD model involving prenatal valproic acid exposure, EE reversed many ASD-like phenotypes, including repetitive behaviors, decreased social interactions and increased anxiety [171] . The restricted and repetitive behaviors seen in ASD may be particularly modifiable by EE [118, 161] . Exercise also has beneficial effects on neural function and neuroplasticity, and may confer resistance to stressful stimuli occurring during crucial developmental periods [116, 153] . For example, symptoms of ADHD show some improvement following bouts of exercise, and scheduled exercise along with EE has been proposed as an adjuvant treatment for ADHD [80] . Clearly, future studies should continue to investigate the remediation of NDDs by environmental factors including EE and exercise in both clinical and preclinical settings, as these may offer cost-effective benefits for the patients.
Emerging translational challenges
Taken together, mounting evidence summarized here demonstrates a complex interplay between genetic and environmental factors underlying NDD pathogenesis in both clinical and preclinical studies ( Fig. 1-2) . The issue of how well animal models translate into clinical NDDs and other brain disorders has already been comprehensively discussed in the literature (including recent reviews of the scope, validity and challenges of translation of preclinical models [103, 104, 136, 181, 191, 192] ), and will not be addressed here. Fully recognizing the existing limitations of animal NDD models, the ISBS Task
Force has emphasized several strategies to address the existing challenges in this field of biological psychiatry. Identified by the Panel as critical areas of research to build translational and cross-diagnostic bridges, these studies can improve markedly our understanding of NDD neurobiology.
Improving the pharmacotherapy of NDDs: understanding molecular targets
Although varying in the central and genetic causes or in their clinical symptoms, NDDs can respond to drug therapies that target discrete deficits ( Table 2 ) [88] . The degree of genetic anomalies and brain pathology underlying NDDs determine the potential targets for pharmacotherapy. For example, comparable cognitive improvements are less likely for NDDs associated with severely underdeveloped brain regions, such as FAS or microcephaly [58] . The prognosis of pharmacotherapy is better for NDDs caused by subtler neural changes that affect the function of local, well-defined neural circuits. Likewise, targeting dysfunction in long-term plasticity, including both synapse strengthening via long-term potentiation and weakening by long-term depression, appears to be rather efficient [124] . In some cases, an effective therapy may involve drugs given to infants or young children [84] , thereby requiring a welltimed diagnosis. Pharmacotherapies that target disrupted equilibrium of neurotransmitter systems also offer promise for NDDs, since drugs that counter such imbalances affect ongoing neural circuit dynamics rather than established gross anatomical abnormalities. Examples of therapeutic strategies in this category include the use of GABA antagonists for Down syndrome [65] , mGluR antagonists for FXS [17] , and norepinephrine reuptake inhibitors for Rett syndrome [165, 202] . Finally, functional homeostatic mechanisms may contribute to the rebalancing of neurotransmitter function after drug therapy [65] , and different therapeutic strategies for NDDs may be required at different stages of life [88] . Thus, a major task is to find a critical 'core' deficit among multiple neurological processes at a sensitive time window in NDDs, and then quickly adjust their pharmacotherapy accordingly.
Expanding NDD spectra beyond traditional diagnostic categories: understanding clinical targets across disorders
Recently developed and promoted by NIMH research diagnostic criteria (RDOCs) [93] emphasize the importance of pathobiological mechanisms and aberrant traits across multiple disorders.
This approach aims to lay a firmer foundation for discovering the distal etiology of brain diseases, which are presently only recognized by their clinical depictions in the DSM and the ICD. Various psychiatric disorders have recently been reconsidered in the context of neural development, as genetic risk and environmental factors may jointly predispose an individual to pathogenesis beyond traditional NDDs, such as depression, anxiety and schizophrenia. For example, early studies have identified an increase in minor physical abnormalities in adult patients with major depression [120] , suggesting some neurodevelopmental origin of depressive symptoms. Although subsequent studies did not replicate these findings [185] , recent hypotheses of depression pathogenesis recognize the importance of early environmental modulation and developmental trajectories in adult affective states [10] . For instance, risks from genes related to monoaminergic neurotransmission and neurotrophic factors, such as BDNF, may be combined with aversive environmental conditions during development, to increase depression risk [89] . Likewise, the neurodevelopmental hypothesis of schizophrenia has gained traction recently, especially as genetic association studies have revealed significant risk overlap with ASD and ID in networks related to chromatin remodeling and synaptic connectivity [1, 68, 130] . Subsequent meta-analysis also revealed significant co-morbidity between ASD and schizophrenia [37] . Genetic schizophrenia risks involve common variation across the genome, particularly in the major histocompatibility complex (MHC) region and the complement component 4 [172, 180] . Genetic predisposition and environmental factors affecting brain development therefore encompass schizophrenia risk, suggesting that NDDs represent, in fact, a much wider 'NDD+' spectrum of abnormalities [140, 147] (Fig. 1 ).
Individuals exposed to intense trauma are also at significant risk for developing post-traumatic stress disorder (PTSD) or other trauma-and stressor-related disorders (TSRDs) [87, 186, 207] . Childhood abuse/trauma can result in an early-onset PTSD, suggesting that this subset of TSRDs may be related to NDDs [8, 27, 151] . TSRDs are difficult to treat because stress interacts with vulnerability factors [62, 112, 159, 160] , differentially affecting traumatized individuals [86, 135, 138, 159] . Neurodevelopmental deficits (e.g., reduced hippocampal volume) per se may predispose individuals to PTSD [27, 135] , with 'early' traumas making it more treatment-resistant [127] . Thus, neurodevelopmental factors may play a dual role in TSRDs: while some stressors may induce them at young age (thereby influencing neural development), other stressors can trigger pathogenesis in vulnerable adults with pre-existing neurodevelopmental abnormalities (Fig. 2) [56, 155, 175, 207] . For example, individual responses to trauma are influenced by a history of childhood abuse or neglect [8, 27, 151] , causing neuroendocrine deficits and dysfunction of forebrain structures (e.g., the hippocampus and prefrontal cortex [25, 26, 194] ), and sensitizing vulnerable individuals to respond more strongly to stress in adulthood [127, 148] .
A recent animal PTSD model utilizes a 1-month daily inescapable confinement of rats close to a cat, combined with daily social stress [208, 209] . Using this and other preclinical TSRD models [49, 155] can be particularly interesting in neurodevelopmental contextse.g., assessing how trauma in mothers affects neural development of offspring, or how early stress in pups alters their adult NDD-related behaviors. Moreover, in addition to NDD-promoting impact of early traumas, it is also possible that, under certain circumstances, such exposure can also increase resistance (somewhat similar to how vaccinations boost the immune system). Therefore, the fine balance between NDD-triggering and protective impacts of early life experiences merits further scrutiny in both clinical and pre-clinical studies.
Accordingly, more 'spectrum-based' integrative animal models to target this growing 'NDD+' group may be needed [102, 181] .
Tracing NDDs across the lifespan: understanding potential therapeutic windows
Other important emerging questions are how the brain develops under healthy conditions, and how this goes awry in NDDs? The former needs to be clear by establishing the latter. As brain development is driven by a complex interplay of genetic and environmental determinants [54, 178] , animal models are particularly useful for tracing neural development across developmental stages. For example, micro-array gene expression and high-throughput RNA-sequencing of the mouse brain across developmental stages, from infancy (postnatal day P7), adolescence (P28) to adulthood (P70), shows that the overall increase in gene expression from infancy to adolescence, which decreases in adulthood [173, 198] ; see Fig. 3 for an overview of gene expression changes across development. The adolescent brain has the most active gene expression, especially of regulatory genes and transcription factors critical for neurogenesis, differentiation, glial lineage determination and circadian rhythm regulation. Compared to infant brains, adolescent and adult brains also show a drastic increase in myelin basic protein-coding gene expression [198] . During infancy and adolescence, gene expression related to axon repulsion and attraction show opposite trends, as axon attraction is activated at the embryonic stage and declines postnatally [198] . Animal studies can detail developmental processes in neurons, astrocytes, microglia, endothelial cells, pericytes and various maturation states of oligodendrocytes, given that the major brain cell classes differ in their developmental processes. In the P7 mouse cortex, RNA sequencing reveals many new cell type-enriched genes and splicing isoforms, substantially enhancing our understanding of brain developmental processes (http://web.stanford.edu/group/barres_lab/brain_rnaseq.html). Novel long non-coding RNAs (lncRNAs) were also identified in proliferating neural stem cells, differentiating progenitors and newborn neurons, which overlapped with neurogenic genes and shared a nearly identical expression pattern [13] . This suggests that lncRNAs control corticogenesis by tuning the expression of nearby cell fate determinants. Finally, during cortical development, a group of novel small non-coding RNAs (sncRNAs) is associated with much higher editing events at late postnatal stages (P7, P14, P28), implicating sncRNA editing in fine tuning of gene expression during the formation of complicated synaptic connections at postnatal stages [199] . Empowered by the availability of in-vivo animal models, such approaches may help improve our understanding of neurodevelopmental trajectories in the healthy 
The role of epigenetic modulation: bridging genetic and pharmacological therapies
As both genetic and environmental factors impose risk for NDDs, epigenetic enzymes and modification rapidly emerge as potential avenues for investigation of biological mechanisms and novel pharmacological therapies. Indeed, mutations in specific epigenetic enzymes may cause some NDDs (e.g., mutations in MECP2 in Rett syndrome) [5] . Recent genome-wide studies have identified de novo mutations in numerous genes involved in chromatin modification present in patients with ASD [24, 50] .
Other genes identified in these same studies include synaptic organization proteins, and it is possible that these two biological networks may be more closely related than previously assumed. For example, the chromatin-modifying gene CHD8, which is associated with ASD, modulates the transcription of other ASD risk genes during neural development [43] . Given the involvement of environmental factors in the etiology of NDDs, epigenetic alterations occurring during early life, from gestation to adolescence and young adulthood, may confer increased or decreased risk for these disorders [43] . As whole-genome sequencing becomes more economically viable, mutations in non-coding, regulatory regions in ASD patients have been observed recently [189] . Additionally, ASD patients show differential expression of lncRNAs compared to controls [195] The notion of transgenerational epigenetic effects, where risk for a disease may be passed along outside of traditional genetic encoding, may also play a role in NDD risk.
For example, prenatal nicotine exposure in rodents causes hyperactivity that resembles ADHD, and this phenotype is inherited (presumably, epigenetically) until at least the third generation via the maternal lineage [204] . Further exploration of epigenetic enzymes, transgenerational effects, and regulatory regions of the genome can shed additional light on the pathogenesis of complex NDDs.
Conclusion
In summary, various genetic and environmental risk factors predispose to NDDs, affecting both the brain development and its mature functioning. Despite the growing scientific inquiry into the pathogenesis of NDDs, their etiology and effective treatment strategies remain unclear. NDDs also significantly overlap with other prevalent psychiatric disorders, including schizophrenia, depression and PTSD, possibly representing an even broader 'NDD+' spectrum of brain maladies resulting from developmental perturbations (Fig. 1 ). Continued effort into improving pharmacotherapy and identifying genetic and environmental risk factors for NDDs will implicate novel biological pathways and, hopefully, The ultimate goals of understanding the etiology of NDDs are to direct treatments at neurodevelopmental deficits, to apply them during a most sensitive time window, and/or early enough in order to prevent or reduce aberrant neural development. Since genes and environmental factors often act prenatally, this may also require 'very early' diagnostic and therapeutic intervention, such as treatment of the mother during pregnancy. However, like using prenatal SSRIs to alleviate maternal depression and protect the fetus for glucocorticoid-mediates changes in neural development [90, 106] , this may also result in a catch-22 situation with side effects of the remedy overweighting its therapeutic action.
Therefore, finding the appropriate intervention before disease symptoms are displayed is not trivial, and must be considered from neurodevelopmental perspective, in addition to other (primary) goals of therapeutic intervention.
On a positive note, children and adults suffering from NDDs may also have their strong phenotypic characteristics. Therefore, rather than only correcting NDD deficits, augmenting the patients' strengths may provide an alternative strategy to increase a patient's well-being. However, this aspect is particularly environment-dependent. For instance, while ASD patients have difficulties with complex information integration, they perform very well when focusing on a task. Likewise, while ADHD children have difficulties in sitting still in the class room, as adults they can do well as managers who have to multitask. Thus, rather than fitting them with the 'standard' environment shaped for the majority of the human population, the ISBS Panel recognizes that providing the special NDD patients with an environment that fosters their capacities may not only down-play their limitations, but also benefit the society, as well as reduce negative (e.g., stress-related) influences, thereby indirectly further alleviating Table 1) . Additional disorders with neurodevelopmental trajectories include bipolar depression (BD) and schizophrenia (SZ), as well as some others, not shown here (e.g., early-onset types of trauma-and stress-related disorders (TSRD)), that forming the wider 'NDD+' spectrum. "umbrella" categories (adapted from [173] and complemented with findings from [198] ). This graph illustrates that gene expression patterns change markedly across development, rendering gene expression data at only one single time point uninformative. Table 1 . Selected genes involved in neurodevelopmental disorders (NDDs). These genes represent those discussed above, and do not serve as an exhaustive list of genetic mutations seen in all the NDDs [88] .
Disorder Genes involves (encoded proteins) Cellular function
Microcephaly CASC5 (Casc5),CEP152 (Centrosomal protein of 152 kDa), STIL (SCL-interrupting locus protein) and others [72, 76, 115, 164] Centrosome/centriole function; Trisomy 21 (~97% of cases) [12] Many genes, including the complement component 4 (C4) in the MHC locus [2, 14] Binding of methylated DNA, modulation of transcription
Various
Neural function and immune regulation
